<DOC>
	<DOCNO>NCT01460836</DOCNO>
	<brief_summary>Matching-adjusted indirect comparison tobramycin solution ( TIS ) versus aztreonam lysine ( AZLI ) use TIS patient level clinical trial data AZLI aggregate clinical trial data publish literature .</brief_summary>
	<brief_title>Indirect Comparison Tobramycin Solution Inhalation Versus Aztreonam Lysine Inhalation Treatment Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Aztreonam</mesh_term>
	<criteria>â‰¥ 6 year age document Cystic fibrosis ( CF ) diagnosis , moderateto severe lung disease , ability perform reproducible pulmonary function test , Pseudomonas aeruginosa ( PA ) airway infection . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Cystic fibrosis</keyword>
</DOC>